Brent Allen Hanks

A phase II pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma, with sequential evaluation of the tumor microenvironment

Indoleamine 2,3-dioxygenase-1 (IDO1) can mediate immune dysfunction by reducing tryptophan (Trp) and increasing kynurenine (Kyn). The CITN-04 clinical trial (NCT01961115) tested the safety and clinical activity of combination therapy with IDO1 inhibitor epacadostat (INCB024360) p...